Kristin Bullok, PhD, is a research scientist in benefit-risk management at Eli Lilly and Company, Global Patient Safety. Since joining Lilly, she has years of combined experience in conducting structured benefit-risk assessments, consulting on patient preference trade-off studies, and developing regulatory scientific communications. She is lead for the scientific dissemination strategy as part of the communications team for PREFER and developing the PREFER framework for preference studies.

Carol Mansfield, PhD, is a Senior Economist and Head in the Health Preference Assessment group at RTI Health Solutions, where she conducts stated-preference studies for pharmaceutical applications. She has more than 25 years of experience conducting research related to health and the environment. She has conducted research to investigate preferences for medications, medical devices, disease prevention programs, children's health, air and water quality protection, recreation experiences, and terrorism risk. Dr. Mansfield has extensive experience with preference elicitation methods, including the design and implementation of surveys, as well as statistical analysis of the responses.

Rachael L. DiSantostefano, MS PhD, is a Senior Director in the Epidemiology Department within Janssen Pharmaceuticals, R&D, LLC. She has more than 25 years of pharmaceutical research experience across the quantitative disciplines of epidemiology, biostatistics, and health outcomes. Currently, she supports Global Public Health. Her work includes epidemiology and drug safety, including benefit-risk assessment and risk-minimization activities. Dr. DiSantostefano is an active member of PREFER, a 5-year public-private partnership that examines how and when to perform and include patient-preference studies in decision making during the medical product life cycle.